- Following the successful TREK-AD Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis, process is underway to identify potential partners.
- Recruitment in TREK-DX, studying eblasakimab in dupilumab-experienced patients, using updated criteria based on findings from TREK-AD, has commenced at US sites, with additional sites in Europe expected to open in the first half of 2024.
- Review of blinded safety data emerging from FAST-AA study of farudodstat in alopecia areata shows no emerging liver or other safety concerns, supporting the broadening of enrollment criteria to include less severe patients. Topline interim data readout is now expected mid-2024.
- Translational work demonstrating eblasakimab’s potential in COPD, with head-to-head data suggesting possible benefits over dupilumab, support potential of eblasakimab to address a wide range of AD comorbidities.
San Mateo, California, and Singapore, December 12, 2023 – ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today provided a business update and updates related to its programs, eblasakimab and farudodstat.
For more information please refer to the press release.